Exploring the potential for subtype-selective muscarinic agonists in glaucoma

Area of Science:

• Ophthalmology
• Pharmacology
• Neuroscience

Background:

• Pilocarpine has been a long-standing treatment for lowering intraocular pressure (IOP) in glaucoma patients.
• Muscarinic receptors, particularly the M3 subtype, are implicated in both IOP reduction and ocular side effects like pupil constriction and lens accommodation.
• The need for treatments that selectively lower IOP without causing these side effects is critical.

Purpose of the Study:

• To investigate a novel muscarinic receptor agonist, AGN 199170, for its potential to lower IOP.
• To compare the efficacy of AGN 199170 with pilocarpine in a glaucoma model.
• To determine if muscarinic agonists targeting receptors other than M3 can selectively reduce IOP.

Main Methods:

• Utilized a monkey glaucoma model to assess the effects of muscarinic receptor agonists on IOP.
• Administered pilocarpine, a known M3 receptor agonist, as a comparative treatment.
• Evaluated the novel agonist AGN 199170, which lacks M3 receptor activity, in the same model.

Main Results:

• Both pilocarpine and AGN 199170 demonstrated the ability to lower intraocular pressure (IOP).
• AGN 199170 achieved IOP reduction despite having no activity on the M3 muscarinic receptor subtype.
• This suggests a potential dissociation between IOP-lowering effects and M3-mediated side effects.

Conclusions:

• Muscarinic agonists targeting receptor subtypes other than M3 may offer a pathway for selective IOP reduction.
• Novel compounds like AGN 199170 hold promise for developing glaucoma therapies with improved side effect profiles.
• Further research into non-M3 muscarinic receptor agonists could lead to more targeted glaucoma treatments.